Amgen | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Amgen | 8-K: Amgen's Board Approves and Amends Equity Incentive Plan
Amgen | DEFA14A: Others
Amgen | DEFA14A: Others
Amgen | 8-K: AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Amgen | DEFA14A: Others
Amgen | DEFA14A: Others
Amgen | DEF 14A: Definitive information statements
Amgen | 8-K: AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
Amgen | 8-K: Amgen Announces Executive Appointments to Accelerate Innovation
Amgen | 8-K: Amgen Reports Third Quarter Financial Results
Amgen | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Amgen | 8-K: Amgen Completes Acquisition of Horizon Therapeutics Plc
Amgen | 8-K: On October 5, 2023, the High Court of Ireland sanctioned the acquire Scheme
Amgen | 8-K: Amgen Inc.、Pillartree Limited entered into certain Transaction Agreement with Horizon Therapeutics plc
Amgen | 8-K: The Irish High Court set a court hearing for October 5, 2023 to consider Horizon’s application for sanction of the proposed scheme of arrangement to effect the Acquisition under Irish law.
Amgen | 8-K: AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION
Amgen | 8-K: The Board of Directors of Amgen Inc. appointed Matthew C. Busch as Vice President, Finance and Chief Accounting Officer
Amgen | 8-K: Amgen REPORTS SECOND QUARTER FINANCIAL RESULTS
Amgen | 8-K: Amgen, Horizon Therapeutics Plc and Pillartree Limited, A Wholly Owned Subsidiary of Amgen Entered into a Transaction Agreement
No Data